Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-01-20

AUTHORS

Masayuki Inoue, Hiroshi Nakagomi, Haruka Nakada, Kazushige Furuya, Kou Ikegame, Hideki Watanabe, Masao Omata, Toshio Oyama

ABSTRACT

BackgroundInvasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.MethodsWe retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor–node–metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER+ or PR+/HER2− subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.ResultsThe clinical stage was significantly higher in the ILC patients than in the IDC (p = 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (p = 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (p = 0.05). In ER+ or PR+/HER2− subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (p = 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (p < 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (p = 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy.ConclusionsThe extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs. More... »

PAGES

667-672

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-017-0753-4

DOI

http://dx.doi.org/10.1007/s12282-017-0753-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1054080971

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28108967


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Ductal, Breast", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Lobular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peritoneal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inoue", 
        "givenName": "Masayuki", 
        "id": "sg:person.01354217107.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354217107.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakagomi", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01152576336.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152576336.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakada", 
        "givenName": "Haruka", 
        "id": "sg:person.01301466667.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301466667.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furuya", 
        "givenName": "Kazushige", 
        "id": "sg:person.01265174206.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265174206.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ikegame", 
        "givenName": "Kou", 
        "id": "sg:person.016412731202.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016412731202.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Hideki", 
        "id": "sg:person.01233353467.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233353467.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Internal Medicine, Yamanashi Prefectural Central Hospital, Kofu, Japan", 
            "University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Omata", 
        "givenName": "Masao", 
        "id": "sg:person.0775700471.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775700471.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oyama", 
        "givenName": "Toshio", 
        "id": "sg:person.011405362052.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011405362052.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2407-10-664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003295205", 
          "https://doi.org/10.1186/1471-2407-10-664"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031850548", 
          "https://doi.org/10.1186/bcr767"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1984.135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051625971", 
          "https://doi.org/10.1038/bjc.1984.135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1986.4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013179959", 
          "https://doi.org/10.1038/bjc.1986.4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7819-5-75", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031914836", 
          "https://doi.org/10.1186/1477-7819-5-75"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-01-20", 
    "datePublishedReg": "2017-01-20", 
    "description": "BackgroundInvasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.MethodsWe retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor\u2013node\u2013metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER+ or PR+/HER2\u2212 subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.ResultsThe clinical stage was significantly higher in the ILC patients than in the IDC (p\u00a0=\u00a00.001). The mean (\u00b1SD) of DFS for the ILC and IDC patients was 2.6\u00a0\u00b1\u00a00.6 and 2.4\u00a0\u00b1\u00a00.3\u00a0years, respectively, with no significant difference (p\u00a0=\u00a00.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (p\u00a0=\u00a00.05). In ER+ or PR+/HER2\u2212 subtype, the mean DFS for the ILC and IDC was 2.9\u00a0\u00b1\u00a00.6 and 3.1\u00a0\u00b1\u00a00.3\u00a0years, and the median survival time after the recurrence for ILC and IDC patients was 4.2\u00a0\u00b1\u00a00.7 and 5.6\u00a0\u00b1\u00a00.7\u00a0years, respectively, with no significant difference (p\u00a0=\u00a00.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (p\u00a0<\u00a00.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (p\u00a0=\u00a00.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19\u00a0\u00b1\u00a09\u00a0months and resistance to hormone therapy.ConclusionsThe extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12282-017-0753-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "disease-free survival", 
      "invasive ductal carcinoma", 
      "metastatic breast cancer", 
      "median survival time", 
      "ILC group", 
      "peritoneal metastasis", 
      "IDC group", 
      "IDC patients", 
      "lobular carcinoma", 
      "progesterone receptor", 
      "breast cancer", 
      "estrogen receptor", 
      "survival time", 
      "human epidermal growth factor 2 (HER2) expression", 
      "mean disease-free survival", 
      "metastatic breast cancer patients", 
      "definitive clinical features", 
      "site of recurrence", 
      "common histological type", 
      "hormone receptor status", 
      "retrospective cohort study", 
      "breast cancer patients", 
      "invasive lobular carcinoma", 
      "growth factor 2 expression", 
      "significant differences", 
      "new therapeutic strategies", 
      "factor 2 expression", 
      "ILC patients", 
      "metastatic disease", 
      "hormone therapy", 
      "cohort study", 
      "clinical features", 
      "patient age", 
      "receptor status", 
      "HER2 positivity", 
      "histological type", 
      "clinical stage", 
      "lung metastases", 
      "ductal carcinoma", 
      "cancer patients", 
      "therapeutic strategies", 
      "patients", 
      "primary site", 
      "metastasis factors", 
      "metastasis", 
      "survival curves", 
      "carcinoma", 
      "recurrence", 
      "high rate", 
      "cancer", 
      "subtypes", 
      "receptors", 
      "group", 
      "years", 
      "prognosis", 
      "therapy", 
      "MethodsWe", 
      "cohort", 
      "disease", 
      "diagnosis", 
      "months", 
      "positivity", 
      "survival", 
      "age", 
      "differences", 
      "definitive features", 
      "rate", 
      "status", 
      "point of development", 
      "expression", 
      "sites", 
      "frequency", 
      "dissemination", 
      "specific sites", 
      "factors", 
      "study", 
      "time", 
      "resistance", 
      "features", 
      "ILC", 
      "stage", 
      "development", 
      "strategies", 
      "types", 
      "curves", 
      "note", 
      "point", 
      "BackgroundInvasive lobular carcinoma", 
      "epidermal growth factor 2 (HER2) expression", 
      "dissemination of ILCs"
    ], 
    "name": "Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer", 
    "pagination": "667-672", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1054080971"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-017-0753-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28108967"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-017-0753-4", 
      "https://app.dimensions.ai/details/publication/pub.1054080971"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_733.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12282-017-0753-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-017-0753-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-017-0753-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-017-0753-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-017-0753-4'


 

This table displays all metadata directly associated to this object as RDF triples.

311 TRIPLES      22 PREDICATES      142 URIs      129 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-017-0753-4 schema:about N013fd165b96c454b84a32561cc1adbb4
2 N11f113916abd43f5874e16b9af4a9b41
3 N20a5d643dab84f91a730cdb858680103
4 N4cc7fb9d8d0a4717bd7539b19d66bf6c
5 N528d105e72f14fbab097ff848a328e13
6 N52e521213b11457d9747f80934bff97f
7 N6b169035f6304f20b0357655351e2b0b
8 N8a8dadc391154191ba337c79da820096
9 N8e8790110a424523b531ca00f22bcef0
10 N96ed01bd522949bd96caf1ec323e38dd
11 N99e6f1aa743142de96fcdf8a8e586086
12 N9b0a2ee0ed3d4a7aace68ab3ca2544e5
13 Nc963909f6e78438f80a27701446c2ba6
14 Nd2559fc5d7a548ada8fbf4351560b8e1
15 Nd720e83acf8c48d88a10416882203ebf
16 Nec1409bc0e7f44669686dcbc67bc210d
17 Necc4aeed89114b9dadadbbe83e39fe8c
18 Nf46013d76d7045f0b7816801fa548e20
19 Nfcd8fb96caba420ea6b47ec78c50763a
20 Nfe254bbe81d546088ae11d1d8f8b67b3
21 Nff46b5a695b24c7085e219c6c9d5dc3e
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N72e20a3e3e464f55b5cf3a1d513b7bc1
25 schema:citation sg:pub.10.1038/bjc.1984.135
26 sg:pub.10.1038/bjc.1986.4
27 sg:pub.10.1186/1471-2407-10-664
28 sg:pub.10.1186/1477-7819-5-75
29 sg:pub.10.1186/bcr767
30 schema:datePublished 2017-01-20
31 schema:datePublishedReg 2017-01-20
32 schema:description BackgroundInvasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.MethodsWe retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor–node–metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER+ or PR+/HER2− subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.ResultsThe clinical stage was significantly higher in the ILC patients than in the IDC (p = 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (p = 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (p = 0.05). In ER+ or PR+/HER2− subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (p = 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (p < 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (p = 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy.ConclusionsThe extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N6abfac10f84a4f00abffe16e29a24045
37 Ne0e39e2c68134364a849a7645d3c1d9c
38 sg:journal.1021080
39 schema:keywords BackgroundInvasive lobular carcinoma
40 HER2 positivity
41 IDC group
42 IDC patients
43 ILC
44 ILC group
45 ILC patients
46 MethodsWe
47 age
48 breast cancer
49 breast cancer patients
50 cancer
51 cancer patients
52 carcinoma
53 clinical features
54 clinical stage
55 cohort
56 cohort study
57 common histological type
58 curves
59 definitive clinical features
60 definitive features
61 development
62 diagnosis
63 differences
64 disease
65 disease-free survival
66 dissemination
67 dissemination of ILCs
68 ductal carcinoma
69 epidermal growth factor 2 (HER2) expression
70 estrogen receptor
71 expression
72 factor 2 expression
73 factors
74 features
75 frequency
76 group
77 growth factor 2 expression
78 high rate
79 histological type
80 hormone receptor status
81 hormone therapy
82 human epidermal growth factor 2 (HER2) expression
83 invasive ductal carcinoma
84 invasive lobular carcinoma
85 lobular carcinoma
86 lung metastases
87 mean disease-free survival
88 median survival time
89 metastasis
90 metastasis factors
91 metastatic breast cancer
92 metastatic breast cancer patients
93 metastatic disease
94 months
95 new therapeutic strategies
96 note
97 patient age
98 patients
99 peritoneal metastasis
100 point
101 point of development
102 positivity
103 primary site
104 progesterone receptor
105 prognosis
106 rate
107 receptor status
108 receptors
109 recurrence
110 resistance
111 retrospective cohort study
112 significant differences
113 site of recurrence
114 sites
115 specific sites
116 stage
117 status
118 strategies
119 study
120 subtypes
121 survival
122 survival curves
123 survival time
124 therapeutic strategies
125 therapy
126 time
127 types
128 years
129 schema:name Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer
130 schema:pagination 667-672
131 schema:productId N0f31b0ca578c4707827880cf3c439560
132 N72e467815b704e6b8dac478061811e20
133 N88af948270b44552bfdf20bdd693b064
134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054080971
135 https://doi.org/10.1007/s12282-017-0753-4
136 schema:sdDatePublished 2021-11-01T18:31
137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
138 schema:sdPublisher N24024fab430a4fbfb4303e6145709a61
139 schema:url https://doi.org/10.1007/s12282-017-0753-4
140 sgo:license sg:explorer/license/
141 sgo:sdDataset articles
142 rdf:type schema:ScholarlyArticle
143 N007ca5225e53439fb0a955bba00fda25 rdf:first sg:person.016412731202.58
144 rdf:rest Nbf52f65e6dff4982825560d145ace157
145 N013fd165b96c454b84a32561cc1adbb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Breast Neoplasms
147 rdf:type schema:DefinedTerm
148 N0f31b0ca578c4707827880cf3c439560 schema:name dimensions_id
149 schema:value pub.1054080971
150 rdf:type schema:PropertyValue
151 N11f113916abd43f5874e16b9af4a9b41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Antineoplastic Agents, Hormonal
153 rdf:type schema:DefinedTerm
154 N20a5d643dab84f91a730cdb858680103 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Carcinoma, Ductal, Breast
156 rdf:type schema:DefinedTerm
157 N24024fab430a4fbfb4303e6145709a61 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 N4ae81cc510764d0a90faa35ca4c3fb9f rdf:first sg:person.01152576336.53
160 rdf:rest N7b7727f4a3bd46fcbbbd5a0dd94ef4e9
161 N4cc7fb9d8d0a4717bd7539b19d66bf6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Receptors, Estrogen
163 rdf:type schema:DefinedTerm
164 N4fee8e4b77404c078dfcf7d3f1d310f4 rdf:first sg:person.01265174206.02
165 rdf:rest N007ca5225e53439fb0a955bba00fda25
166 N528d105e72f14fbab097ff848a328e13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Prognosis
168 rdf:type schema:DefinedTerm
169 N52e521213b11457d9747f80934bff97f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 N6570baf89bde4ceb9aeb1c18414b1a66 rdf:first sg:person.011405362052.18
173 rdf:rest rdf:nil
174 N6abfac10f84a4f00abffe16e29a24045 schema:volumeNumber 24
175 rdf:type schema:PublicationVolume
176 N6b169035f6304f20b0357655351e2b0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Lymphatic Metastasis
178 rdf:type schema:DefinedTerm
179 N72e20a3e3e464f55b5cf3a1d513b7bc1 rdf:first sg:person.01354217107.78
180 rdf:rest N4ae81cc510764d0a90faa35ca4c3fb9f
181 N72e467815b704e6b8dac478061811e20 schema:name pubmed_id
182 schema:value 28108967
183 rdf:type schema:PropertyValue
184 N7b7727f4a3bd46fcbbbd5a0dd94ef4e9 rdf:first sg:person.01301466667.87
185 rdf:rest N4fee8e4b77404c078dfcf7d3f1d310f4
186 N88af948270b44552bfdf20bdd693b064 schema:name doi
187 schema:value 10.1007/s12282-017-0753-4
188 rdf:type schema:PropertyValue
189 N8a8dadc391154191ba337c79da820096 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Carcinoma, Lobular
191 rdf:type schema:DefinedTerm
192 N8e8790110a424523b531ca00f22bcef0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Lung Neoplasms
194 rdf:type schema:DefinedTerm
195 N96ed01bd522949bd96caf1ec323e38dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Peritoneal Neoplasms
197 rdf:type schema:DefinedTerm
198 N99e6f1aa743142de96fcdf8a8e586086 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Treatment Outcome
200 rdf:type schema:DefinedTerm
201 N9b0a2ee0ed3d4a7aace68ab3ca2544e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Humans
203 rdf:type schema:DefinedTerm
204 Nbf52f65e6dff4982825560d145ace157 rdf:first sg:person.01233353467.08
205 rdf:rest Nce650740e1b04764b871bbb01ecfd211
206 Nc963909f6e78438f80a27701446c2ba6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Disease-Free Survival
208 rdf:type schema:DefinedTerm
209 Nce650740e1b04764b871bbb01ecfd211 rdf:first sg:person.0775700471.08
210 rdf:rest N6570baf89bde4ceb9aeb1c18414b1a66
211 Nd2559fc5d7a548ada8fbf4351560b8e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Receptors, Progesterone
213 rdf:type schema:DefinedTerm
214 Nd720e83acf8c48d88a10416882203ebf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Retrospective Studies
216 rdf:type schema:DefinedTerm
217 Ne0e39e2c68134364a849a7645d3c1d9c schema:issueNumber 5
218 rdf:type schema:PublicationIssue
219 Nec1409bc0e7f44669686dcbc67bc210d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Middle Aged
221 rdf:type schema:DefinedTerm
222 Necc4aeed89114b9dadadbbe83e39fe8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Neoplasm Recurrence, Local
224 rdf:type schema:DefinedTerm
225 Nf46013d76d7045f0b7816801fa548e20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Follow-Up Studies
227 rdf:type schema:DefinedTerm
228 Nfcd8fb96caba420ea6b47ec78c50763a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
229 schema:name Adult
230 rdf:type schema:DefinedTerm
231 Nfe254bbe81d546088ae11d1d8f8b67b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Aged
233 rdf:type schema:DefinedTerm
234 Nff46b5a695b24c7085e219c6c9d5dc3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Receptor, ErbB-2
236 rdf:type schema:DefinedTerm
237 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
238 schema:name Medical and Health Sciences
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
241 schema:name Oncology and Carcinogenesis
242 rdf:type schema:DefinedTerm
243 sg:journal.1021080 schema:issn 1340-6868
244 1880-4233
245 schema:name Breast Cancer
246 schema:publisher Springer Nature
247 rdf:type schema:Periodical
248 sg:person.011405362052.18 schema:affiliation grid-institutes:grid.417333.1
249 schema:familyName Oyama
250 schema:givenName Toshio
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011405362052.18
252 rdf:type schema:Person
253 sg:person.01152576336.53 schema:affiliation grid-institutes:grid.417333.1
254 schema:familyName Nakagomi
255 schema:givenName Hiroshi
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152576336.53
257 rdf:type schema:Person
258 sg:person.01233353467.08 schema:affiliation grid-institutes:grid.417333.1
259 schema:familyName Watanabe
260 schema:givenName Hideki
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233353467.08
262 rdf:type schema:Person
263 sg:person.01265174206.02 schema:affiliation grid-institutes:grid.417333.1
264 schema:familyName Furuya
265 schema:givenName Kazushige
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265174206.02
267 rdf:type schema:Person
268 sg:person.01301466667.87 schema:affiliation grid-institutes:grid.417333.1
269 schema:familyName Nakada
270 schema:givenName Haruka
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301466667.87
272 rdf:type schema:Person
273 sg:person.01354217107.78 schema:affiliation grid-institutes:grid.417333.1
274 schema:familyName Inoue
275 schema:givenName Masayuki
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354217107.78
277 rdf:type schema:Person
278 sg:person.016412731202.58 schema:affiliation grid-institutes:grid.417333.1
279 schema:familyName Ikegame
280 schema:givenName Kou
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016412731202.58
282 rdf:type schema:Person
283 sg:person.0775700471.08 schema:affiliation grid-institutes:grid.26999.3d
284 schema:familyName Omata
285 schema:givenName Masao
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775700471.08
287 rdf:type schema:Person
288 sg:pub.10.1038/bjc.1984.135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051625971
289 https://doi.org/10.1038/bjc.1984.135
290 rdf:type schema:CreativeWork
291 sg:pub.10.1038/bjc.1986.4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013179959
292 https://doi.org/10.1038/bjc.1986.4
293 rdf:type schema:CreativeWork
294 sg:pub.10.1186/1471-2407-10-664 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003295205
295 https://doi.org/10.1186/1471-2407-10-664
296 rdf:type schema:CreativeWork
297 sg:pub.10.1186/1477-7819-5-75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031914836
298 https://doi.org/10.1186/1477-7819-5-75
299 rdf:type schema:CreativeWork
300 sg:pub.10.1186/bcr767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031850548
301 https://doi.org/10.1186/bcr767
302 rdf:type schema:CreativeWork
303 grid-institutes:grid.26999.3d schema:alternateName University of Tokyo, Tokyo, Japan
304 schema:name Department of Internal Medicine, Yamanashi Prefectural Central Hospital, Kofu, Japan
305 University of Tokyo, Tokyo, Japan
306 rdf:type schema:Organization
307 grid-institutes:grid.417333.1 schema:alternateName Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan
308 Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan
309 schema:name Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan
310 Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan
311 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...